Leap Therapeutics Inc. (Nasdaq: LPTX)

https://www.leaptx.com

Leap Therapeutics is an immuno-oncology company with two clinical stage programs. Leap’s most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in esophageal cancer and cholangiocarcinoma. Leap’s second clinical candidate, TRX518, is a novel, humanized GITR agonist monoclonal antibody designed to enhance the immune system’s anti-tumor response. TRX518 is in clinical trials in patients with advanced solid tumors. *

	Start	2016-08-29 existent
	Industry	BIOTECH
	Industry 2	DKN-01 anti-DKK humanised MAb (Leap Therapeutics)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	47 Thorndike Street Suite B1-1
	City	02141 Cambridge, MA
	Tel	+1-617-714-0360
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-07-10

Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px

More documents for Leap Therapeutics Inc. (Nasdaq: LPTX)

[1] Leap Therapeutics, Inc.. (1/17/23). "Press Release: Leap Therapeutics Acquires Flame Biosciences". Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]